Compare Amphastar Pharmaceuticals Inc (AMPH) vs OneSpan Inc (OSPN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Amphastar Pharmaceuticals Inc vs OneSpan Inc — how do they compare? Amphastar Pharmaceuticals Inc trades at $20.39 (market cap $863.95M), while OneSpan Inc trades at $16.25 (market cap $603.27M). The key difference: Amphastar Pharmaceuticals Inc is the larger of the two by market cap, and OneSpan Inc pays a 3.18% dividend while Amphastar Pharmaceuticals Inc pays none. Which is the better fit depends on your goals.
| AMPH | OSPN | |
|---|---|---|
Market Cap | $863.95M | $603.27M |
Sector | Health | Technology |
52-Week High | $30.81 | $16.78 |
52-Week Low | $16.87 | $10.15 |
Enterprise Value | $1.26B | $572.35M |
Dividend Yield | — | 3.18% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AMPH trades at $20.78, up 4.9% today, with a bullish technical signal supported by moving averages. The stock shows mixed earnings performance with Q2 2026 beating estimates but Q1 and Q4 2025 missing. Fundamentals remain solid with a 10.76% net margin and reasonable valuation at 12.02 P/E. Recent news highlights Q2 2026 results and strategic shift toward proprietary drugs.
Outlook is cautiously optimistic with growth supported by new product launches, though regulatory risks and earnings volatility pose challenges. Analyst sentiment is mixed with 25% buy ratings but majority hold recommendations. The stock offers value but requires monitoring of FDA developments and earnings consistency.
OneSpan (OSPN) trades at $16.78, up 3.33% today, with a bullish technical outlook and strong analyst support. The stock exhibits robust fundamentals, including a P/E of 9.25, net income margin of 27.76%, and consistent earnings beats in recent quarters. Recent news highlights Q2 2026 revenue growth and raised full-year guidance, reflecting positive business momentum.
The outlook is positive, driven by earnings strength and strategic initiatives, but risks include competitive pressures and potential margin compression. With a consensus price target of $17.00 and 67% buy ratings, Wall Street sees modest upside from current levels amid overall solid financial health.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Amphastar Pharmaceuticals Inc
Amphastar is a specialty pharmaceutical company that develops and markets injectable, intranasal, and inhalation products. Its portfolio includes both complex generic drugs and proprietary delivery systems.
Read more on AMPH →About OneSpan Inc
OneSpan Inc. is a global leader in providing digital agreement security solutions. The company's platform helps organizations, primarily in the financial services sector, to secure their digital agreements and transactions, including e-signatures, multi-factor authentication, and transaction monitoring. OneSpan's technology is focused on protecting customers from fraud and meeting regulatory compliance requirements in a digital-first environment.
Read more on OSPN →
